Patents by Inventor Rajesh Kumar Badange

Rajesh Kumar Badange has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED AZACYCLES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20210369685
    Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the methods of preparation, pharmaceutical composition, combinations and the use of compound formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 21, 2018
    Publication date: December 2, 2021
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Rajesh Kumar BADANGE, Raghava Choudary PALACHARLA, Venkateswarlu JASTI
  • Muscarinic M1 receptor positive allosteric modulators
    Patent number: 11040026
    Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: June 22, 2021
    Assignee: Suven Life Sciences Limited
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Rajesh Kumar Badange, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
  • Fluoropiperidine compounds as pure 5-HT 6 receptor antagonists
    Patent number: 10973831
    Abstract: The present invention relates to fluoropiperidine compounds of formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof as 5-HT6 receptor antagonists. In particular the present invention discloses the methods of preparation, pharmaceutical composition, combinations and use of fluoropiperidine compounds, their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: April 13, 2021
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Rajesh Kumar Badange, Kumar Bojja, Vinod Kumar Goyal, Santosh Kumar Pandey, Jagadeesh Babu Thentu, Venkateswarlu Jasti
  • FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT 6 RECEPTOR ANTAGONISTS
    Publication number: 20200155560
    Abstract: The present invention relates to fluoropiperidine compounds of formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof as 5-HT6 receptor antagonists. In particular the present invention discloses the methods of preparation, pharmaceutical composition, combinations and use of fluoropiperidine compounds, their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 6, 2018
    Publication date: May 21, 2020
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Rajesh Kumar BADANGE, Kumar BOJJA, Vinod Kumar GOYAL, Santosh Kumar PANDEY, Jagadeesh Babu THENTU, Venkateswarlu JASTI
  • MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20190343812
    Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).
    Type: Application
    Filed: August 31, 2017
    Publication date: November 14, 2019
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Rajesh Kumar BADANGE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
  • Sulfone compounds as 5-HT6 receptor ligands
    Patent number: 9018231
    Abstract: The present invention relates to novel sulfone compounds as 5-HT6 receptor ligands of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment/prevention of various disorders that are related to 5-HT6 receptor functions.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: April 28, 2015
    Assignee: Suven Life Sciences Limited
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Rama Sastri Kambhampati, Rajesh Kumar Badange, Veena Reballi, Anil Kashinath Chindhe, Rambabu Namala, Mohamad Sadik Abdulhamid Mulla, Ishtiyaque Ahmad, Renny Abraham, Venkateswarlu Jasti
  • SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS
    Publication number: 20130005709
    Abstract: The present invention relates to novel sulfone compounds as 5-HT6 receptor ligands of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment/prevention of various disorders that are related to 5-HT6 receptor functions.
    Type: Application
    Filed: March 24, 2010
    Publication date: January 3, 2013
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Rama Sastri Kambhampati, Rajesh Kumar Badange, Veena Reballi, Anil Kashinath Chindhe, Rambabu Namala, Mohamad Sadik Abdulhamid Mulla, Ishtiyaque Ahmad, Renny Abraham, Venkateswarlu Jasti